Norwest Venture Partners led a $96m Series D round in Nectero Medical.

Norwest Venture Partners, an American venture and growth equity investment firm, led a $96m Series D round in Nectero Medical, a clinical-stage biotechnology company, with participation from Boston Scientific Corporation, BioStar Capital, Cadence Healthcare Ventures and Aphelion Capital. “We are pleased to have raised the funds required to complete the necessary work to bring our potentially transformative technology to market. In addition, we are fortunate to add two highly knowledgeable and extremely insightful members to our already strong and accomplished Board of Directors,” Jack Springer, Nectero Medical President & CEO.